Patents by Inventor Ulrich Möbius
Ulrich Möbius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240100180Abstract: The invention provides an ADC based on an antibody binding to CLDN18.2, wherein the antibody or fragment thereof exhibits increased binding to tumor tissue expressing CLDN18.2 over healthy tissue expressing CLDN18.2.Type: ApplicationFiled: December 23, 2021Publication date: March 28, 2024Inventors: Lukas Bammert, Lenka Kyrych Sadilkova, Simona Hoskova, Iva Valentova, Lorenz Waldmeier, Roger Beerli, Ulrich Moebius
-
Publication number: 20240034783Abstract: The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.Type: ApplicationFiled: December 23, 2020Publication date: February 1, 2024Inventors: Lukas Bammert, Lenka Kyrych Sadilkova, Simona Hoskova, Iva Valentova, Lorenz Waldmeier, Roger Beerli, Ulrich Moebius
-
Publication number: 20230398185Abstract: The present invention relates to an interleukin-2/interleukin-15 receptor ?? (IL-2/IL-15R??) agonist for use in the treatment of non-melanoma skin cancer. Further provided are dosing schemes for treating patients with non-melanoma skin cancer with an IL-2/IL-15R?? agonist.Type: ApplicationFiled: October 26, 2021Publication date: December 14, 2023Inventors: Stefano FERRARA, Ulrich MOEBIUS, David BÉCHARD, Irena ADKINS, Nada PODZIMKOVA
-
Publication number: 20230390361Abstract: The present invention relates to an interleutkin-2/interleutkin-15 receptor ?? (IL-2/IL-15R??) agonist for use in the treatment of squamous cell carcinoma. Further provided are dosing schemes for treating patients with squamous cell carcinoma with an IL-2/IL-15R?? agonist.Type: ApplicationFiled: October 26, 2021Publication date: December 7, 2023Inventors: Stefano FERRARA, Ulrich MOEBIUS, David BÉCHARD, Irena ADKINS, Nada PODZIMKOVA
-
Publication number: 20230030674Abstract: The invention provides humanized antibodies binding to CLDN18.2 with a high affinity. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.Type: ApplicationFiled: December 7, 2020Publication date: February 2, 2023Inventors: Lukas Bammert, Lenka Kyrych Sadilkova, Lorenz Waldmeier, Roger Beerli, Ulrich Moebius
-
Publication number: 20220241375Abstract: The present invention provides pulsed cyclic administration regimes and pulsed administration regimes for interleukin-2/interleukin-15 receptor ?? (IL-2/IL-15R??) agonists for treating or managing cancer or infectious diseases in human patients. The administration regimes inter alia involve daily administration of IL-2/IL-15R?? agonists on 2, 3 or 4 consecutive days followed by days without administration.Type: ApplicationFiled: May 20, 2020Publication date: August 4, 2022Inventors: Ulrich MOEBIUS, David BECHARD, Irena ADKINS, Nada PODZIMKOVA
-
Publication number: 20210198380Abstract: The disclosure provides a fusion polypeptide specific for both CD137 and HER2/neu, which fusion polypeptide can be useful for directing CD137 clustering and activation to HER2/neu-positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.Type: ApplicationFiled: November 12, 2020Publication date: July 1, 2021Inventors: Marlon Hinner, Christine Rothe, Shane Olwill, Rachida Siham Bel Aiba, Ulrich Moebius, Corinna Schlosser, Thomas Jean Jaquin
-
Patent number: 10865250Abstract: The disclosure provides a fusion polypeptide specific for both CD137 and HER2/neu, which fusion polypeptide can be useful for directing CD137 clustering and activation to HER2/neu-positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.Type: GrantFiled: May 4, 2016Date of Patent: December 15, 2020Assignee: Pieris Pharmaceuticals GmbHInventors: Marlon Hinner, Christine Rothe, Shane Olwill, Rachida Siham Bel Aiba, Ulrich Moebius, Corinna Schlosser, Thomas Jean Jaquin
-
Publication number: 20200054552Abstract: The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m—O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p [CH2—R3]-group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/orType: ApplicationFiled: August 19, 2019Publication date: February 20, 2020Inventors: Yunik CHANG, Robert LATHROP, Erwin BOHM, Irene GANDER-MEISTERERNST, Regina GREGER, Johanna HOLLDACK, Ulrich MOEBIUS
-
Patent number: 10434059Abstract: The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m-O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—R3]— group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/orType: GrantFiled: August 18, 2017Date of Patent: October 8, 2019Assignee: Fougera Pharmaceuticals Inc.Inventors: Yunik Chang, Robert Lathrop, Erwin Böhm, Irene Gander-Meisterernst, Regina Greger, Johanna Holldack, Ulrich Moebius
-
Publication number: 20190010248Abstract: The disclosure provides a fusion polypeptide specific for both CD137 and HER2/neu, which fusion polypeptide can be useful for directing CD137 clustering and activation to HER2/neu-positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.Type: ApplicationFiled: May 4, 2016Publication date: January 10, 2019Applicant: Pieris Pharmaceuticals GmbHInventors: Marlon HINNER, Christine ROTHE, Shane OLWILL, Siham Rachida BEL AIBA, Ulrich MOEBIUS, Corinna SCHLOSSER, Jean Thomas JAQUIN
-
Publication number: 20180193254Abstract: The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m-O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p [CH2—R3]— group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/oType: ApplicationFiled: August 18, 2017Publication date: July 12, 2018Applicant: Fougera Pharmaceuticals Inc.Inventors: Yunik CHANG, Robert LATHROP, Erwin BÖHM, Irene GANDER-MEISTERERNST, Regina GREGER, Johanna HOLLDACK, Ulrich MOEBIUS
-
Patent number: 9770406Abstract: The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m-O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—R3]- group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/orType: GrantFiled: September 21, 2010Date of Patent: September 26, 2017Assignee: Medigene AGInventors: Yunik Chang, Robert Lathrop, Erwin Böhm, Irene Gander-Meisterernst, Regina Greger, Johanna Holldack, Ulrich Moebius
-
Patent number: 9260521Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: GrantFiled: October 3, 2013Date of Patent: February 16, 2016Assignees: MEDIGENE AG, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFUNG DES OFFENTLICHEN RECHTSInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Publication number: 20140120117Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: ApplicationFiled: October 3, 2013Publication date: May 1, 2014Applicants: MediGene AG, Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen RechtsInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Breitling, Achim Krueger, Silke Baerreiter, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Patent number: 8580258Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: GrantFiled: February 6, 2012Date of Patent: November 12, 2013Assignees: Deutsches krebsforschungszentrum Stiftung des Offentlichen Rechts, Medigene AGInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krueger, Silke Wolterink, Sandra Luettgau, Ulrich Moebius, Yi Li, Susanne Sebens, Heiner Schaefer
-
Patent number: 8138313Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: GrantFiled: June 13, 2008Date of Patent: March 20, 2012Assignees: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts, MediGene AGInventors: Daniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krüger, Silke Bärreiter, Sandra Lüttgau, Ulrich Möbius, Yi Li
-
Publication number: 20110009481Abstract: The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m-O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—R3]- group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/orType: ApplicationFiled: September 21, 2010Publication date: January 13, 2011Applicant: MediGene AGInventors: Yunik Chang, Robert Lathrop, Erwin Böhm, Irene Gander-Meisterernst, Regina Greger, Johanna Holldack, Ulrich Moebius
-
Patent number: 7858662Abstract: The invention relates to a medicament containing a compound of general formula (1), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkynyl group, preferably a C11-C15 alkyl, alkylene or alkynyl group, particularly a C11-C13 alkyl, alkylene or alkynyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkynyl group, preferably a C1-C6 alkyl, alkylene or alkynyl group, in particular a C2-C4 alkyl, alkylene or alkynyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m—O]nH group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—(R3)]— group, where R3=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tuType: GrantFiled: November 18, 2002Date of Patent: December 28, 2010Assignee: MediGene AGInventors: Yunik Chang, Robert Lathrop, Erwin Böhm, Irene Gander-Meisterernst, Regina Greger, Johanna Holldack, Ulrich Moebius
-
Publication number: 20100105123Abstract: The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof.Type: ApplicationFiled: September 24, 2007Publication date: April 29, 2010Applicant: MEDIGENE AKTIENGESELLSCHAFTInventors: Michael Hallek, Anne Girod, Martin Ried, Christof Stolla, Ulrich Moebius